% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Claassen:304116,
      author       = {K. Claassen and C. Justenhoven and S. Hermann$^*$ and J.
                      Brandhorst$^*$ and J. Lakes and D. Werner and H. Kajüter
                      and M. Karpinski and V. Arndt$^*$ and A. Stang and P.
                      Albers},
      title        = {{T}he {P}robability of {R}emaining {U}nder {A}ctive
                      {S}urveillance for {L}ocalized {P}rostate {C}ancer: {A}n
                      {A}nalysis of {Y}oung {P}atients in the {F}ramework of the
                      {M}ulticenter {P}roju{M}a {R}egistry {S}tudy.},
      journal      = {Deutsches Ärzteblatt international},
      volume       = {122},
      number       = {15},
      issn         = {1866-0452},
      address      = {Köln},
      publisher    = {Dt. Ärzte-Verl.},
      reportid     = {DKFZ-2025-01779},
      pages        = {401-405},
      year         = {2025},
      note         = {German Cancer ResearchCenter (DKFZ), Epidemi-ological
                      Cancer Registry},
      abstract     = {After a diagnosis of prostate cancer, the 15-year
                      cancer-specific survival probability is high; in suitable
                      patients, active surveillance lessens the side effects of
                      curative treatment. Limited evidence is available on the
                      continuation of active surveillance in young prostate cancer
                      patients in Germany.Using data that were reported, as
                      required by law, to the population-based cancer registries
                      of the German federal states of North Rhine-Westphalia,
                      Baden-Württemberg, and Rhineland- - Palatinate, we studied
                      the course of 732 patients under 60 years of age who were
                      under active surveillance after receiving a diagnosis of
                      low-risk localized prostate cancer (ISUP grade 1 or 2) in
                      the years 2016-2021.The median duration of follow-up was 28
                      months. $64\%$ $[61\%;$ $68\%]$ of the patients were still
                      under active surveillance at two years; this was true for
                      $66\%$ $[62\%;$ $70\%]$ of those with ISUP grade 1 disease,
                      $46\%$ $[37\%;$ $58\%]$ of those with ISUP grade 2 disease,
                      and $72\%$ $[63\%;$ $83\%]$ of those for whom no Gleason
                      grading was available. $62\%$ of discontinuations occurred
                      without any documented progression and without a documented
                      patient-initiated decision.The two-year probability of young
                      prostate cancer patients remaining under active surveillance
                      was lower in Germany than in other countries. The cancer
                      registries mostly received no information concerning the
                      clinical rationale for the discontin uations. The
                      potentially incomplete reporting of reasons for
                      discontinuing active surveillance suggests that clinical
                      reporting practices should be improved.},
      keywords     = {Humans / Male / Prostatic Neoplasms: mortality / Prostatic
                      Neoplasms: therapy / Prostatic Neoplasms: epidemiology /
                      Prostatic Neoplasms: diagnosis / Prostatic Neoplasms:
                      pathology / Registries: statistics $\&$ numerical data /
                      Germany: epidemiology / Watchful Waiting: statistics $\&$
                      numerical data / Middle Aged / Adult / Survival Rate},
      cin          = {M110},
      ddc          = {610},
      cid          = {I:(DE-He78)M110-20160331},
      pnm          = {319H - Addenda (POF4-319H)},
      pid          = {G:(DE-HGF)POF4-319H},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40493882},
      doi          = {10.3238/arztebl.m2025.0081},
      url          = {https://inrepo02.dkfz.de/record/304116},
}